Heart Test Laboratories: AI-Driven Cardiology Platform Nearing Regulatory Milestones Supports Upside and Buy Rating
I'm PortAI, I can summarize articles.
Ascendiant analyst Lucas Ward maintains a Buy rating on Heart Test Laboratories (HSCS) due to operational progress and upside potential. The company outperformed Q2 FY26 earnings expectations and is advancing its MyoVista Insights platform with AI capabilities. A recent 510(k) submission for MyoVista wavECG hardware is a key milestone, with FDA clearance expected in 2026. Despite financing and execution risks, Ward's analysis supports a price target of $9.20, triple the current share price. Maxim Group also reiterates a Buy rating with a $12.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments